Retension Pharmaceuticals (RTSN) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $87.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RTSN | UPB |
|---|---|---|
| Share price | $10.51 | $1.59 |
| Market cap | $87.57M | $87.15M |
| 1-day change | -19.22% | -20.50% |
| YTD return | — | -94.14% |
| 1-year return | — | -93.78% |
| EPS (TTM) | $-2.61 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | — | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $18.64 | $33.68 |
| 52-week low | $9.23 | $1.56 |
| Distance from 52-week high | -43.62% | -95.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +391.63% | +1245.91% |
| Average volume | 144.93K | 1.01M |
| Shares outstanding | 8.33M | 54.81M |
| Employees | 12 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
RTSN vs UPB FAQ
Which is bigger, Retension Pharmaceuticals or Upstream Bio?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $87.15M for Upstream Bio (UPB).
Are Retension Pharmaceuticals and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.